Sinovac surges on positive Phase III data for lead HFMD vaccine
This article was originally published in Scrip
Executive Summary
Shares in Sinovac Biotech jumped by 60% at one point after the Chinese vaccines firm said that the efficacy and safety of its experimental Enterovirus 71 prophylactic vaccine for human hand, food and mouth disease (HFMD) had been confirmed in a Phase III trial.